Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02490748

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Cervical Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

30 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

About this study

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cervical cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer.

they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer).

Exclusion criteria

  • studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.

Treatment and study plan

Radiofrequency ablation

Procedure

Radiofrequency ablation is performed percutaneously under CT/US guidance

Other names: RFA

Cytokine-Induced Killer Cells

Biological

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Other names: CIK

Primary outcomes

  1. Recurrence-free survival

    Time frame: 1 year

    Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Sponsors and collaborators

Lead sponsor

The First People's Hospital of Changzhou

Other

Registry information

Official study title

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Important dates

Study start
2015
Primary completion
2038
Study completion
2040
First posted
Jul 7, 2015
Registry last updated
Feb 23, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.